Ramalingam, Suresh S <br/><br/>
Osimertinib As First-Line Treatment of EGFR Mutation-Positive Advanced Non-Small-Cell Lung Cancer.  [electronic resource] 

 -  Journal of clinical oncology : official journal of the American Society of Clinical Oncology  03 2018 
 - 841-849 p.  digital 
<br/><br/> Publication Type: Clinical Trial; Journal Article; Research Support, Non-U.S. Gov't 
<br/><br/><label>ISSN: </label>1527-7755 
<br/><br/><label>Standard No.: </label>10.1200/JCO.2017.74.7576  doi 
<br/><br/><label>Subjects--Topical Terms: </label><br/>Acrylamides<br/>Adult<br/>Aged<br/>Aged, 80 and over<br/>Aniline Compounds<br/>Antineoplastic Agents--therapeutic use<br/>Carcinoma, Non-Small-Cell Lung--drug therapy<br/>ErbB Receptors--blood<br/>Female<br/>Humans<br/>Lung Neoplasms--drug therapy<br/>Male<br/>Middle Aged<br/>Mutation<br/>Piperazines--therapeutic use<br/>Progression-Free Survival<br/>Protein Kinase Inhibitors--therapeutic use<br/>Survival Rate